HYBRID EVENT: You can participate in person at Rome, Itlay or Virtually from your home or work.

11th Edition of International Conference on

Neurology and Neurological Disorders

June 05-07, 2025 | Rome, Italy

Genetics In Neurodegenerative Disorder

Genetics In Neurodegenerative Disorder

Neurodegenerative diseases refer to a group of progressive conditions that cause the neurons in the brain and spinal cord to deteriorate over time. These diseases not only cause physical and cognitive impairments but also lead to significant emotional stress and an overall decline in quality of life. Over the last few years, genetics has been pinpointed as an obvious factor in the pathogenesis of these diseases. The discovery of genetic links to neurodegenerative disorders has led to an increased focus on the role of genetic risk factors in disease susceptibility. Genetic mutations, deletions, and alterations have been identified for many neurodegenerative diseases, such as Huntington’s disease, Alzheimer’s disease, and Parkinson’s disease. For instance, the Huntington’s disease-causing CAG repeat mutation is located in the Huntington’s gene. This gene codes for the enzyme Huntingtin, which is found in large concentrations in the brain and implicated in the disease pathogenesis. Parkinson’s disease is linked to several mutations on at least four genes. The most important of these is the LRRK2 gene, which carries a greater risk of developing Parkinson’s compared to other genes. For Alzheimer’s disease, a mutation in the ApoE gene has been found to increase the risk of developing the disease. Furthermore, other genes implicated in the disease's risk include APP, PSEN1, and PSEN2. With the advancements in genetic research and testing, doctors and scientists may be able to develop preventive strategies, appropriate treatments, and even cures for neurodegenerative disorders. The insight gained from genetic studies can help researchers design targeted therapies, unravel pathways involved in the pathogenesis of such diseases, and help patients make informed decisions regarding their health. At the same time, genetic testing for neurodegenerative diseases does come with certain risks, such as having to cope with an unexpected diagnosis, stigma, and anxiety. Thus, genetic testing should only be conducted after taking into consideration the emotional and physical impact it may have on an individual.

Committee Members
Speaker at Neurology and Neurological Disorders 2025 - Ken Ware

Ken Ware

NeuroPhysics Therapy Institute, Australia
Speaker at Neurology and Neurological Disorders 2025 - Robert B Slocum

Robert B Slocum

University of Kentucky HealthCare, United States
Speaker at Neurology and Neurological Disorders 2025 - Luiz Moutinho

Luiz Moutinho

University of Suffolk, United Kingdom
Neurology 2025 Speakers
Speaker at Neurology and Neurological Disorders 2025 - David Lominadze

David Lominadze

University of South Florida, United States
Speaker at Neurology and Neurological Disorders 2025 - Milton C R Medeiros

Milton C R Medeiros

Irmandade Santa Casa de Arapongas PR, Brazil
Speaker at Neurology and Neurological Disorders 2025 - Sang Hie Lee

Sang Hie Lee

University of South Florida, United States
Speaker at Neurology and Neurological Disorders 2025 - Sergei M Danilov

Sergei M Danilov

University of Illinois, United States
Tags

Submit your abstract Today

Watsapp